Dianosic key facts
as of Oct 2026- Developer of medical devices designed to serve in the treatment of ENT conditions.
- Dianosic is valued at approximately $8.2M as of Oct 2026 (last reported valuation).
- It has raised $15.0M; the latest was Debt - General in Jan 2025.
- Notable investors include Bpifrance, Noshaq, Capital Grand Est, Caisse d'Epargne, Banque Populaire Rives de Paris — 17 tracked in total.
- Status: Privately Held (backing).
Dianosic's last reported valuation, Oct 2022. Nothing priced has surfaced since.
- ·The complete investor list: 17 names
- ·Watch Dianosic: the Monday email on marks, rounds and moves
Dianosic funding rounds
No funding rounds for Dianosic are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Dianosic
17+Dianosic valuation
Dianosic's last reported valuation was $8.2 million in Oct 2022. No priced round, secondary trade or fund mark has surfaced since.
Dianosic investors
17 investors are on record for Dianosic, including Bpifrance, Noshaq, Capital Grand Est and Caisse d'Epargne.
About Dianosic
Developer of medical devices designed to serve in the treatment of ENT conditions. The company's platform offers an alternative to daily medication by designing a unique sustained intranasal drug delivery solution for respiratory and chronic central nervous system diseases, its active resorbable intranasal scaffold device includes asymmetric balloons to treat nosebleeds and active resorbable scaffolds that treat chronic sinusitis, allergic rhinitis, and intranasal bleeding, enabling doctors to remotely follow patients out of the hospital and keep track of their health.
- Sector
- Healthcare
- HQ
- Strasbourg, France
- Founded
- 2017
- Employees
- 12
- Website
- dianosic.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.